Clinical Trials Logo

Clinical Trial Summary

This is a multicenter, open-label, phase I/II basket study, evaluating the safety, tolerability, RP2D, pharmacokinetics, pharmacodynamics and antitumor activity of EOS-448 combined with standard of care and/or with investigational therapies in participants with advanced solid tumors.: EOS-448 will be combined with pembrolizumab, a marketed anti-PD-1 antibody in one treatment arm and a second treatment arm will evaluate EOS-448 combined with inupadenant, an investigational adenosine A2A receptor antagonist.


Clinical Trial Description

The study will be conducted in multiple staged parts: - Part 1 consists of two dose finding cohorts evaluating safety and tolerability as well as determining the recommended phase 2 dose (RP2D) of EOS-448 combined with pembrolizumab (Part 1A) or with inupadenant (Part 1B), in participants with advanced solid tumors. - Part 2 is the expansion part of the study. It will further explore the safety, tolerability, anti-tumor activity as well as pharmacokinetics and pharmacodynamics of EOS-448 combined with pembrolizumab in participants with PD-L1 positive first line (1L) mNSCLC (Part 2A and 2B) or in participants with PD-L1 positive 1L mHNSCC (Part 2C and 2D) and, of EOS-448 combined with inupadenant in participants with anti-PD-(L)1 resistant metastatic cutaneous melanoma (Part 2E), treated at the respective combinations RP2D. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05060432
Study type Interventional
Source iTeos Therapeutics
Contact Clarisse Truong
Phone 0032477892186
Email [email protected]
Status Recruiting
Phase Phase 1/Phase 2
Start date September 6, 2021
Completion date September 2024

See also
  Status Clinical Trial Phase
Completed NCT03918538 - A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors N/A
Recruiting NCT05078918 - Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors N/A
Recruiting NCT04548830 - Safety of Lung Cryobiopsy in People With Cancer Phase 2
Completed NCT04633850 - Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
Completed NCT00245154 - Paclitaxel + Carboplatin With/Out Cediranib Maleate in Stage III or Stage IV Non-Small Cell Lung Cancer Phase 2/Phase 3
Active, not recruiting NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Recruiting NCT03575793 - A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer Phase 1/Phase 2
Recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Terminated NCT01624090 - Mithramycin for Lung, Esophagus, and Other Chest Cancers Phase 2
Terminated NCT03275688 - NanoSpectrometer Biomarker Discovery and Confirmation Study
Completed NCT01000025 - PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Metastatic Cancer Phase 3
Not yet recruiting NCT04934865 - Real Life Study Evaluating the Clinical and Organisational Impact of Moovcare® Lung Connected Medical Device in Lung Cancer Patients : REAL-MOOV-LUNG N/A
Not yet recruiting NCT04563234 - Perioperative Cognitive Training in Thoracic Surgery N/A
Recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Active, not recruiting NCT02196844 - Yoga Program for Lung Cancer Patients and Caregivers N/A
Recruiting NCT04500535 - A Study of Participants With Advanced Non-Small Cell Lung Cancer Treated With Nivolumab in France After at Least One Prior Chemotherapy-based Treatment by Lung Initiative on Sequence Therapy
Recruiting NCT04957433 - 'Lung Health Check' Biomarker Study
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT03317080 - Dynamic Monitoring Circulating Tumor DNA in Surgical Patients With Lung Cancer
Recruiting NCT04104516 - Lifestyle Modification Program for Lung Cancer Patients - Physical Activity Preference